NEWS-Regen BioPharma, Inc. Researchers Discover New Dynamic Compound Which Modulates the NR2F6 CheckpointFont 8:00 AM ET 7/12/17 | Dow Jones
New compound appears to be 10-fold more effective than previous compounds tested while showing no toxicity.
SAN DIEGO, July 12, 2017 /PRNewswire/ --
Regen BioPharma Inc. (OTCQB: RGBP) and (OTCQB: RGBPP), today reported continued progress in developing small molecule drugs that activate and inhibit NR2F6. The Company reports that using a focused compound library and Regen's patented screening methodology, it has identified a dynamic new chemical compound series that modulates NR2F6.
The NR2F6 nuclear receptor has been identified as a potentially very important immune cell inhibitor (an immune checkpoint) and cancer stem cell differentiator. The NR2F6 program at Regen aims to identify antagonists of NR2F6 in an effort to unleash the cancer-killing potential of a patient's own immune system as well as identifying agonists, which should suppress the immune system in diseases where the immune system is over-activated, such as autoimmunity.
"We have identified a particularly active series of NR2F6 activators, which are not toxic and have an ability to activate NR2F6 approximately 10 times more effectively than seen with our previous series," says Harry Lander, Ph.D., MBA, President and Chief Scientific Officer of Regen. "Of particular interest is the parent structure that this series contains. It leads us to believe that we may now understand the structural basis for activating NR2F6."
"I am very pleased that our science continues to advance positively," says David Koos, Ph.D., Chairman & CEO Regen BioPharma Inc. "ChemDiv's expertise in compound optimization has been a great asset as we refine our small molecule drug development program. We continue to expect 2017 to be an extremely important year in Regen's history. Studies were conducted for Regen by ChemDiv, Inc. (an internationally recognized contract research organization) which has been retained by Regen."
